ISOLDA NG: Open Payments
NPI 1487175196 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,714 in 41 payments from 8 companies in 2025. Trend: 2023 $502 · 2024 $1,220 · 2025 $1,714
Food & beverage: $1,714
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 8 | $424 |
| BridgeBio Pharma, Inc. | 15 | $364 |
| CVRx, Inc. | 3 | $308 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $254 |
| AstraZeneca Pharmaceuticals LP | 4 | $149 |
| SCPHARMACEUTICALS INC. | 1 | $128 |
| Alnylam Pharmaceuticals Inc. | 2 | $54 |
| E.R. Squibb & Sons, L.L.C. | 1 | $34 |
Products named: Attruby, Barostim Neo System, CARDIOMEMS, JARDIANCE, FUROSCIX, TRICLIP, AMVUTTRA, CAMZYOS.
Industry payments across NY — which companies pay providers there.
